"Rifamycins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of ANTI-BACTERIAL AGENTS characterized by a chromophoric naphthohydroquinone group spanned by an aliphatic bridge not previously found in other known ANTI-BACTERIAL AGENTS. They have been isolated from fermentation broths of Streptomyces mediterranei.
| Descriptor ID |
D012294
|
| MeSH Number(s) |
D03.633.400.811 D04.345.295.750
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Rifamycins".
Below are MeSH descriptors whose meaning is more specific than "Rifamycins".
This graph shows the total number of publications written about "Rifamycins" by people in this website by year, and whether "Rifamycins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 1 | 0 | 1 |
| 2017 | 6 | 1 | 7 |
| 2018 | 3 | 1 | 4 |
| 2019 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Rifamycins" by people in Profiles.
-
Rifamycin SV exhibits strong anti-inflammatory in vitro activity through pregnane X receptor stimulation and NF?B inhibition. Drug Metab Pharmacokinet. 2019 Jun; 34(3):172-180.
-
Deciphering the late steps of rifamycin biosynthesis. Nat Commun. 2018 06 14; 9(1):2342.
-
The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn's disease. Expert Opin Investig Drugs. 2018 06; 27(6):543-551.
-
New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases. Dig Liver Dis. 2018 08; 50(8):741-749.
-
Beneficial effects of Rifaximin in post-infectious irritable bowel syndrome mouse model beyond gut microbiota. J Gastroenterol Hepatol. 2018 Feb; 33(2):443-452.
-
Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017 Oct; 29(10):1109-1117.
-
A meta-analysis of the use of rifaximin to prevent travellers' diarrhoea. J Travel Med. 2017 Sep 01; 24(5).
-
Rifaximin Re-treatment in Patients with Irritable Bowel Syndrome: Feels Like the First Time? Dig Dis Sci. 2017 09; 62(9):2220-2222.
-
Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation. World J Gastroenterol. 2017 Jul 07; 23(25):4491-4499.
-
Antiretroviral treatment in HIV-infected children who require a rifamycin-containing regimen for tuberculosis. Expert Opin Pharmacother. 2017 Apr; 18(6):589-598.